Effects of Paclitaxel-eluting stent on blood vessel endothelial function

Abstract

Abstract: AIM:To investigate the effects of Paclitaxel- eluting stent on blood vessel endothelial function. METHODS:From July to December in 2006, 72 patients with coronary arteriongraphy of Nanjing Angiocardiopathy Hospital were selected into the clinical study, 48 patients who accepted percutaneous coronary intervene(PCI) in coronary artery were randomly divided into Paclitaxel-eluting stent (PES) Group and Bare metal stent (BMS) Group, 24 patients each group, the other 24 normal patients were assigned into Control Group. The endothelium-dependent flow mediated dilation(FMD) and endothelium-independent nitroglycerinmediated dilation (NMD) of brachial artery 1 day and 6 months after operation were assessed by high-resolution color Doppler ultrosound. The endothelium-dependent vasomotion and endothelium-independent vasomotion of a coronary segment were assessed with quantitative coronary angiography (QCA) immediately after the operation and at 6months follow-up, after intracoronary infusion of acetylcholine and nitroglycerin. RESULTS: 6 months after the operation, compared with Control patients with PCI had lower FMD (5. 7% ± 3. 2% vs 11. 4% ±4. 2%, P <0. 001), but NMD did not significantly differ between groups(P >0. 05). For PES Group, FMD of the first day after operation and at the follow-up 6 months were 8. 7% ±2. 9% vs 4. 6% ±2. 3% (P <0. 05), while BMS Group, FMD of the first day after operation and at the follow-up 6 months had no significant difference(P >0. 05). Compared with BMS group, PES group had lower FMD at the follow-up 6 months (4. 6% ±2. 3% vs 7. 8% ± 3. 4%, P <0. 001), but NMD had no significant difference between groups (P >0. 05). For PES Group, the endothelium-dependent vasomotion (intr-acoronary infusion of acetylcholine) of immediately after the operation and at the follow-up 6 months were-8% ±2% vs-32% ±3% (P <0. 001), while BMS Group, the endothelium-dependent vasomotion of the first day after operation and at the follow-up 6 months did not differ significantly(P >0. 05). Compared with BMS Group, PES Group had lower endothelium-dependent vasomotion(intracoronary infusion of acetylcholine) at the follow- up 6 months(-32% ±3% vs-6% ±3%, P < 0. 001), but there were not significant difference in endothelium- independent vasomotion (P > 0. 05). CONCLUSION:The blood vessel endothelial function was impaired at 6 months after Paclitaxel-eluting stent implantation.

Key words: Paclitaxel-eluting stent, bare metal stent, blood vessel endothelial dysfunction, endothelium- dependent vasomotion, endothelium-independent vasomotion

CLC Number:

GE Zhen, CHEN Shao-liang, LIU Zhi-zhong, ZHANG Jun-jie, CHEN Liang, ZHANG Juan, LI Yuqiao. Effects of Paclitaxel-eluting stent on blood vessel endothelial function[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(5): 563-568.

References

[1] Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J]. N Engl J Med, 2002, 346(23): 1773-1780.
[2] Moses JW, LeonMB, Popma JJ, et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J]. N Engl J Med, 2003, 349 (14): 1315-1323.
[3] Park SJ, Shim WH, Ho DS, et al.A paclitaxel-eluting stent for the prevention of coronary restenosis[J]. N Engl JMed, 2003, 348(16): 1537-1545.
[4] Carter AJ, Aggarwal M, Kopia GA, et al.Long-time effects of polymer-based, slow-release, Sirolimus-eluting stents in a porcine coronary model[J]. Cardiovasc Res, 2004, 63 (4): 617-624.
[5] Togni M, Windecker S, Cocchia R, et al.Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction[J]. J Am Coll Cardiol, 2005, 46(2): 231-236.
[6] Togni M, Räber L, Cocchia R, et al. Local vascular dysfun- ction after coronary paclitaxel-eluting stent implantation [J]. Int J Cardiol, 2006, 120(2): 212-220.
[7] Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus- eluting stent implantation[J]. Eur Heart J, 2006, 27 (2): 166-170.
[8] Celermajer DS, Sorensen K, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J]. Lancet, 1992, 340 (8828): 1111-1115.
[9] McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy[J]. Lancet, 2004, 364(9444): 1519-1521.
[10] Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent [J]. Circulation, 2001, 104(4): 473-479.
[11] Virmani R, Liistro F, Stankovic G, et al.Mechanism of late in-stent restenosis after implantation of a paclitaxel deri- vate-eluting polymer stent system in humans[J]. Circulation, 2002, 106(21): 2649-2651.
[12] Colombo A, Orlic D, Stankovic G, et al.Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation [J]. Circulation, 2003, 107(17): 2178-2180.
[13] Faulx MD,Wright RVT, Hoit BD, et al.Detection of endothe- lial dysfunction with brachial artery ultrasound scanning[J]. Am Heart J, 2003, 145(6): 943-951.
[14] Bonetti PO, Lerman LO, Lerman A.Endothelial dysfunction: a marker of atherosclerotic risk[J]. Arterioscler Thromb Vasc Biol, 2003, 23(2): 168-175.
[15] Maier W, Windecker S, Kung A, et al.Exercise-induced coronary artery vasodilation is not impaired by stent placement[J]. Circulation, 2002, 105(20): 2373-2377.
[16] Guba M, Von Breitenbuch P, Steinbaur M, et al. Rapamycin inhibits primary and metastatic tumer growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med, 2002, 8(2): 128-135.
[17] Gössl M, Rosol M, Malyar NM, et al. Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries[J]. Anat Rec Part A, 2003, 272(8): 526-537.